Global Markets Direct’s, ‘Osteogenesis Imperfecta - Pipeline Review, H1 2019’, provides an overview of the Osteogenesis Imperfecta pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the rep...

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history ...

Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Pipeline Review, H1 2019’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additiona...

Global Markets Direct’s, ‘Fabry Disease - Pipeline Review, H1 2019’, provides an overview of the Fabry Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of ke...

Global Markets Direct’s, ‘Familial Adenomatous Polyposis - Pipeline Review, H1 2019’, provides an overview of the Familial Adenomatous Polyposis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. ...

Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Pipeline Review, H1 2019’, provides an overview of the Primary Immune Deficiency (PID) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press release...

Global Markets Direct’s, ‘Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2019’, provides in depth analysis on Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and...

Global Markets Direct’s, ‘Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2019’, provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complet...

Global Markets Direct’s, ‘P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2019’, provides in depth analysis on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in ...

Global Markets Direct’s, ‘P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019’, provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overvi...

Global Markets Direct’s, ‘Becker Muscular Dystrophy - Pipeline Review, H1 2019’, provides an overview of the Becker Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, t...

Global Markets Direct’s, ‘Crigler-Najjar Syndrome - Pipeline Review, H1 2019’, provides an overview of the Crigler-Najjar Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the rep...

Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2019’, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additiona...

Global Markets Direct’s, ‘Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H1 2019’, provides in depth analysis on Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics,...

Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2019’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics. The report provides comprehensive...